

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Idelalisib may be associated with an increased risk for _____.
 - a. Neutropenia
 - b. Colitis
 - c. Hepatotoxicity
 - d. Opportunistic infections
 - e. All of the above
2. Which of the following statements is true regarding the Phase III RELEVANCE study comparing R² to rituximab/chemotherapy, each followed by maintenance rituximab, for previously untreated FL?
 - a. R² significantly improved progression-free survival
 - b. R² significantly improved the CR rate
 - c. R² and rituximab/chemotherapy demonstrated similar efficacy
3. The phase III GALLIUM study comparing first-line obinutuzumab-based chemotherapy to rituximab-based chemotherapy, followed by obinutuzumab or rituximab maintenance, demonstrated no difference in progression-free survival.
 - a. True
 - b. False
4. A recent study by Schuster and colleagues published in *The New England Journal of Medicine* evaluating the efficacy of CAR T-cell therapy in patients with refractory diffuse large B-cell lymphoma or FL reported a CR rate of approximately _____ in the FL cohort.
 - a. 30%
 - b. 50%
 - c. 70%
5. The ongoing AUGMENT trial is evaluating the R² regimen versus rituximab alone for patients with indolent non-Hodgkin lymphoma in which setting?
 - a. First line
 - b. Relapsed/refractory disease
6. Side effects associated with lenalidomide include _____.
 - a. Neutropenia
 - b. Constipation
 - c. Diarrhea
 - d. All of the above
 - e. Both a and c
7. What is the mechanism of action of tazemetostat, an agent that has shown promising response rates in the treatment of relapsed/refractory FL?
 - a. Immune checkpoint inhibitor
 - b. Antibody-drug conjugate
 - c. EZH2 inhibitor
8. In the RELEVANCE trial, the toxicity profile of the R² regimen was observed to be similar to that of rituximab/chemotherapy, with similar rates of neutropenia, diarrhea and alopecia.
 - a. True
 - b. False
9. Which statement is true regarding copanlisib in the treatment of FL?
 - a. It is administered orally
 - b. It inhibits the alpha and delta isoforms of PI3 kinase
 - c. It may be associated with hyperglycemia and hypertension
 - d. All of the above
 - e. Both a and b
 - f. Both b and c
10. What was the duration of maintenance therapy with rituximab in both the PRIMA and RELEVANCE trials?
 - a. 12 months
 - b. 18 months
 - c. 24 months